China channel feed

Hutchmed files for $600M+ IPO in Hong Kong as lead on­col­o­gy drug su­r­u­fa­tinib awaits FDA's good graces

4 years ago
Financing

Trail­ing the Big Phar­ma play­ers, a less­er known BC­MA CAR-T can­di­date comes in­to the spot­light

4 years ago
R&D
Cell/Gene Tx

No­vo Hold­ings, Vi­vo lead a record $200M raise for a Sin­ga­pore-based tools play­er with plans for a Boston hub, new deals

4 years ago
Financing
Outsourcing

Per­cep­tive's Chi­na up­start Lian­Bio con­tin­ues swing­ing deals, team­ing up with lead Xon­toge­ny biotech Lan­dos in IBD

4 years ago
Deals

Ki­nase in­hibitor spe­cial­ist Kin­nate launch­es Shang­hai sub­sidiary with $35M to mar­ket its pro­grams in Chi­na

4 years ago
Financing

Saman­tha Du's Quan Cap­i­tal, Lil­ly Asia back Chi­na's first big kid­ney play

4 years ago
Financing

Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech crossover fund

5 years ago
Financing

Eli Lil­ly seeds a well-con­nect­ed Chi­na neu­ro start­up with drugs aim­ing at where Bio­gen, Voy­ager missed

5 years ago
Deals

Trans-Pa­cif­ic bis­pe­cif­ic play­er caps 'very chal­leng­ing' pan­dem­ic year with $120M to gain a foothold among the gi­ants

5 years ago

Roger Perl­mut­ter’s lat­est ‘re­tire­ment’ gig opens a door to the bustling Chi­na biotech scene

5 years ago
Bioregnum
Opinion

Chi­na's Yisheng­Bio chron­i­cles come­back sto­ry in Hong Kong IPO while plot­ting big moves in in­fec­tious dis­eases, can­cer

5 years ago
Financing

An­gling Pfiz­er, As­traZeneca jumps in­to com­mer­cial PD-(L)1 fight in Chi­na

5 years ago
Deals
Pharma

Six years sep­a­rat­ed from a ra­bies vac­cine scan­dal, Chi­na’s Yisheng­Bio grabs $130M to go big in in­fec­tious dis­eases, can­cer

5 years ago
Financing

A month af­ter mul­ti-bil­lion dol­lar No­var­tis deal, BeiGene fol­lows up with 're­verse' deal

5 years ago
Deals

Months af­ter shock­ing house ar­rest, Leg­end co-founder Frank Zhang is out on bail — though the CAR-T play­er has moved on

5 years ago
People

A syn­thet­ic lethal­i­ty play­er emerges in Chi­na, armed with lessons on un­drug­gable onco­gene from No­bel lau­re­ate's lab

5 years ago
Financing
Startups

In­novent and Lil­ly win sec­ond Chi­na OK for Tyvyt in front­line NSCLC, ramp­ing up pres­sure on king Keytru­da

5 years ago
FDA+

Nas­daq rings in its first biotech IPOs of 2021: a CAR-T spe­cial­ist from Chi­na, a can­cer port­fo­lio play, and a SPAC

5 years ago
Financing
Cell/Gene Tx

Fast-ex­pand­ing Shang­hai Phar­ma breaks ground on $1.8B biotech park fo­cused on next-gen R&D, an­ti­body pro­duc­tion

5 years ago
Manufacturing

Months af­ter strik­ing SHP2 deal with Ab­b­Vie, Ja­co­bio pulls in $174M+ from Hong Kong IPO

5 years ago
Financing

A boom­ing mar­ket pro­pels Chi­na CRO to a $100M raise. Is an IPO next?

5 years ago
Financing
Outsourcing

Ab­b­Vie's Covid-19 an­ti­body part­ner wraps $221M Hong Kong IPO

5 years ago
Financing

Go­ing to Chi­na? ADC Ther­a­peu­tics spot­lights a new way to do it with Hill­house-backed Over­land

5 years ago
Deals

'S­cale and speed': Hill­house puts its weight be­hind Chi­na start­up eye­ing cut­ting-edge tech from around the world

5 years ago
Startups
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times